UNCY - Unicycive Therapeutics, Inc.

6.59
-0.240   -3.642%

Share volume: 688,758
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$6.83
-0.24
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 50%
Dept financing 31%
Liquidity 58%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.72%
1 Month
-0.15%
3 Months
0.15%
6 Months
50.80%
1 Year
1,068.23%
2 Year
339.33%
Key data
Stock price
$6.59
P/E Ratio 
0.00
DAY RANGE
$6.48 - $6.85
EPS 
-$0.86
52 WEEK RANGE
$0.45 - $8.25
52 WEEK CHANGE
$1,113.63
MARKET CAP 
78.765 M
YIELD 
N/A
SHARES OUTSTANDING 
21.491 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
1.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$549,414
AVERAGE 30 VOLUME 
$520,569
Company detail
CEO: Shalabh Gupta
Region: US
Website: unicycive.com
Employees: 9
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Unicycive Therapeutics, Inc. engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California.

Recent news